Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant
| Status: | Terminated |
|---|---|
| Conditions: | Blood Cancer, Lymphoma, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | September 2012 |
| End Date: | October 2015 |
Nestle Impact has shown efficacy in multiple surgical trials in relation to improving
hospital length of stay and infection rate. 1 dose of Nestle Impact Advanced Recovery will
be taken orally three times a day beginning on the morning following stem cell transplant
and will continue until the day of hospital discharge.
hospital length of stay and infection rate. 1 dose of Nestle Impact Advanced Recovery will
be taken orally three times a day beginning on the morning following stem cell transplant
and will continue until the day of hospital discharge.
Inclusion Criteria:
- Patients receiving an autologous stem cell transplant using the preparative regimens
of BEAM (Carmustine, Etoposide, Cytarabine, Melphalan), Melphalan 140mg/m2, or
Melphalan 200mg/m2
- Any prior diet or supplement will be allowed.
- Age >18 years.
- Ability to understand and the willingness to sign a written informed consent
document.
Exclusion Criteria:
- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to Nestle Impact including fish oil.
We found this trial at
1
site
Click here to add this to my saved trials
